Welcome to

Our website ensures an easy ordering process for affordable HIV/AIDS and PrEP medications, as well as protection of our customers' information. Having an account on our website allows you to place your orders easily, upload your prescriptions safely, view your order history, and even earn discounts.

If you have not ordered from us before:
You can create an account for free by clicking here.

Please take a moment to learn how to order. If you have any trouble, please call us at 1-888-243-7675.

Australia: +61 (2) 90537441 Switzerland: +41 (44) 7982088

We invite you to explore our website and save money on your HIV/AIDS and PrEP medications!

Abacavir/Lamivudine/Zidovudine 300/150/300mg
60 tablet(s)

Abacavir/Lamivudine/Zidovudine 300/150/300mg

$859.99 USD
+ shipping and handling
0 Review(s)

Prescription required

Active Ingredient(s): abacavir/lamivudine/zidovudine
Manufacturer: Apotex
Brand: Generic
Country of origin: Canada
Known Names: Trizivir
60 tablet(s)
Active Ingredient(s): abacavir/lamivudine/zidovudine
Manufacturer: Apotex
Brand: Generic
Country of origin: Canada
Knows Names: Trizivir

What is Abacavir/Lamivudine/Zidovudine?

Abacavir/lamivudine/zidovudine is a combination formulation of the Nucleotide and Nucleoside Reverse Transcriptase Inhibitors (NRTIs), indicated for the treatment of HIV-1 infection, in combination with other antiretroviral drugs.

Dosing & Administration

Abacavir/lamivudine/zidovudine is indicated for the treatment of HIV-1 infection in adults and adolescents weighing 40 Kg or more. The dose is one tablet orally twice a day, with or without food. Because some components require dose adjustments in patients with liver or kidney dysfunction, this formulation is not recommended for use in these patients.


Abacavir/lamivudine/zidovudine is contraindicated in patients with a hypersensitivity to any of the components should not take this drug, and in patients with very low neutrophil or hemoglobin levels.

Abacavir/Lamivudine/Zidovudine Side Effects

The drug is associated with serious side effects, as described below. 

Severe side effects

  • myopathy/myositis,
  • headache,
  • fatigue/weakness,
  • nausea/vomiting,
  • dizziness,
  • loss of appetite,
  • diarrhea.

A detailed list of potential adverse events is available in the product monograph.


Patients should be screened for HLA-B*5701 prior to starting abacavir/lamivudine/zidovudine, due to the risk of serious hypersensitivity reaction to abacavir.

This medication may cause bone marrow suppression, and should be used with caution in patients with baseline bone marrow suppression, or those at risk. Therapy with abacavir/lamivudine/zidovudine requires frequent monitoring of laboratory indices of bone marrow function in all patients, as detailed in the product monograph.

This HIV medication should not be used in patients with liver dysfunction due to risk of hepatotoxicity or lactic acidosis. Recommendations for screening and monitoring are outlined in the product monograph.

Discontinuation of lamivudine (a component of Abacavir/lamivudine/zidovudine) in patients co-infected with HIV and Hepatitis B virus (HBV) may lead to HBV exacerbation. Fatal cases have been reported. Monitoring recommendations for co-infected patients who discontinue Abacavir/lamivudine/zidovudine are listed in the product monograph.

The drug should be used with caution in patients requiring dental work due to the risk of myelosuppression and infection.

All patients who test positive for HIV infection should be screened for comorbid HBV and Hepatitis C virus (HCV) infection. Co-infected patients should be started on an antiretroviral regimen targeting co-infected viruses, regardless of CD4 counts or viral loads. Current HIV treatment guidelines outline drug regimens and prescribing considerations.

Drug Interactions

Abacavir/lamivudine/zidovudine is associated with a large number of drug-drug and herbal interactions. A complete list is provided in the product monograph.

Pregnancy & Lactation

Highly active retroviral combination treatment should be used in all pregnant women. Data from the Antiretroviral Pregnancy Registry do not show that any of the components of abacavir/lamivudine/zidovudine cause major birth defects above baseline. Components of this drug are excreted in breast milk. The CDC recommends that all HIV positive women, treated or untreated, avoid breastfeeding to prevent vertical transmission of the virus.


There is no known treatment specific for abacavir/lamivudine/zidovudine overdose. Patients should be closely monitored and provided with supportive care. None of the components of abacavir/lamivudine/zidovudine appear to be removed by hemodialysis.

Alternative Brand Names

Abacavir/lamivudine/zidovudine 300/150/300mg is available under the brand name Trizivir.

Reset your password

Please enter your email below, and we will send you a new password.

Still having trouble signing in?

If you're unable to reset your password, please call Customer Service at 1-888-243-7675.